Tradjenta and Basal cell carcinoma - a phase IV clinical study of FDA data

Summary:

Basal cell carcinoma is reported as a side effect among people who take Tradjenta (linagliptin), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Amlodipine, and have Polycythaemia vera.

The phase IV clinical study analyzes which people have Basal cell carcinoma when taking Tradjenta. It is created by eHealthMe based on reports of 9,889 people who have side effects when taking Tradjenta from the FDA, and is updated regularly.

What is Tradjenta?

Tradjenta has active ingredients of linagliptin. It is often used in diabetes. eHealthMe is studying from 9,987 Tradjenta users. Check the latest studies of Tradjenta.

What is Basal cell carcinoma?

Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills) is found to be associated with 1,093 drugs and 1,381 conditions by eHealthMe. Check the latest studies of Basal cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

9,889 people reported to have side effects when taking Tradjenta.
Among them, 19 people (0.19%) have Basal cell carcinoma.

Could Tradjenta cause Basal cell carcinoma?

Among these 19 people:

How long have people been on Tradjenta when they have Basal cell carcinoma? *

What is the gender of people who have Basal cell carcinoma when taking Tradjenta? *

female: 42.86 %
male: 57.14 %

What is the age of people who have Basal cell carcinoma when taking Tradjenta? *

What are other drugs people take besides Tradjenta? *

What are other side effects people have besides Basal cell carcinoma? *

Fatigue (feeling of tiredness): 16 people, 84.21%
Dizziness: 12 people, 63.16%
Weakness: 12 people, 63.16%
Rashes (redness): 12 people, 63.16%
Fall: 9 people, 47.37%
Headache (pain in head): 9 people, 47.37%
High Blood Cholesterol: 8 people, 42.11%
Upper Respiratory Tract Infection: 8 people, 42.11%
Scab (a hard coating on the skin formed during the wound healing): 8 people, 42.11%
Balance Disorder: 8 people, 42.11%

What are the existing conditions these people have? *

Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 12 people, 63.16%
Upper Respiratory Tract Infection: 8 people, 42.11%
Pain: 8 people, 42.11%
Blood Uric Acid Increased: 8 people, 42.11%
High Blood Pressure: 5 people, 26.32%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 15.79%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 15.79%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 15.79%
Skin Cancer: 2 people, 10.53%
Thrombocytopenia (decrease of platelets in blood): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Tradjenta and have Basal cell carcinoma?

- Check whether Basal cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tradjenta:

Tradjenta (9,987 reports)

Browse all side effects of Tradjenta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Basal cell carcinoma:

Basal cell carcinoma (1,093 drugs)

Browse all the conditions that are associated with Basal cell carcinoma:

Basal cell carcinoma (1,381 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on linagliptin (the active ingredients of Tradjenta) and Tradjenta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.